Rating: Neutral | Target Price: HKD 8.2–8.9 (base-case fair value range) | Current Price: HKD 8.31 (closing price on 2026-10-30) | Time Horizon: 12 months | Margin of Safety: approximately -1.3% (base-case fair value floor of HKD 8.2 is below the current price — no meaningful margin of safety)
SMOORE International is the global leader in e-vapor device ODM manufacturing, standing at the intersection of two forces: "the HNB (heat-not-burn) second growth curve going from 0 to 1 + the launch of the US compliance inflection" on one side, and "the zeroing-out of export tax rebates in April 2027 + high customer concentration" on the other. Directionally, the inflection is real: HNB revenue grew from RMB 220 million in 2024 to RMB 1,287 million in 2025, reaching RMB 1,358 million in 9M26; after the FDA authorized flavored products in May 2026 and updated its enforcement guidance, the company began delivering flavored products to core customers in Q3. However, the current price of HKD 8.31 has largely priced in the base-case recovery scenario: net of cash, the operating business at approximately RMB 28.7 billion corresponds to 18.4x TTM adjusted net profit (roughly 25–26x excluding share-based compensation), implying the market requires 25–50% adjusted earnings growth in 2027–28, while TTM adjusted net profit grew only +1.8% YoY and gross margin remains in a downtrend. We estimate a base-case fair value of HKD 8.2–8.9 and a probability-weighted fair value of approximately HKD 7.85 (current price is about 6% above it) — odds slightly negative. Neutral rating; await the March 2027 annual report to validate the tax rebate pass-through rate and the slope of the US recovery. Upside options (China's HNB national standard landing in 2027, potential carve-out of the medical platform) and downside risks (insufficient rebate pass-through, HNB single-customer volatility) are broadly symmetric.
Key evidence:
HNB's growth from RMB 220 million in 2024 to RMB 1,358 million in 9M26 (+37.6%) is unquestionably the largest change in the revenue mix. But three constraints must be stated upfront: First, industry beta does not equal company alpha — in 2025 global HNB volume, PMI held roughly 71.5%, BAT roughly 10.7%, and JT roughly 7.1%; SMOORE's publicly verifiable binding is effectively with BAT's glo Hilo system, the smallest-share player. JT's and PMI's high growth has no SMOORE-announcement-level evidence (the second customer's identity is undisclosed; market chatter points to KT&G or JT's Ploom, both unconfirmed rumors). Second, the revenue line is labeled "products and technical services," including R&D/technical service fees (NRE), so growth includes one-off components. Third, the quarterly cadence is driven by a single customer's ordering — Q1 2026 HNB revenue of RMB 664 million accounted for 69% of H1; Q2 fell 55% QoQ and Q3 rose 33% QoQ — the ±50% swings reflect distribution cadence, not the demand curve. China's mandatory national standard for "heated cigarettes" has advanced to WTO/TBT notification (2026-08-19); if it lands in 2027 it would open a third growth pole, but there is no announcement-level evidence that SMOORE can enter China Tobacco's supply chain.
Key evidence:
Judgment on the direction of the US market (20.7% of company revenue in 2026H1) is one of the biggest points of divergence between this report and the bear case. The evidence chain supporting the inflection: illicit products account for roughly 70% of the US vapor market (BAT estimate), creating huge shakeout headroom; in May 2026 the FDA authorized non-tobacco, non-menthol flavored products for the first time and updated its enforcement guidance; the company began delivering flavored products to a core customer in Q3, and e-vapor ODM revenue turned positive at +1.8% YoY in Q3. However, two legal fragilities must be presented honestly: the four products authorized in May 2026 belong to non-core customer Glas (the first non-tobacco flavor authorization was actually NJOY menthol in June 2024); SMOORE's customers' flavored products are on the market under "applications accepted and filed, not currently prioritized for enforcement" — this is enforcement discretion, not PMTA authorization, and could reverse overnight with FDA personnel and policy changes. Moreover, NJOY ACE, manufactured by SMOORE, has been banned from sale since March 2025 due to an ITC patent ruling; the company has not broken down how much of the -15.6% YoY decline in US ToB revenue in 2026H1 was customers' "proactive portfolio adjustment" versus the patent ban and end-market share loss. Whether US revenue can stop falling and rebound in 2027 requires validation from Q4 updates and the annual report — hence the lower confidence.
Key evidence:
Exports account for roughly 90% of SMOORE's total revenue, and the rebate going from 13% to zero is settled legal fact. At pass-through rates of 35%/60%/85%, the impact on 2027 attributable net profit is approximately -670/-410/-150 million RMB (the neutral case equals roughly 27% of the midpoint of our 2027E attributable profit); assuming exports are 90% of 2025 revenue (approximately RMB 12.8 billion) with zero pass-through, the theoretical maximum impact is about RMB 1.4 billion. The wide range reflects two undisclosed variables: the product-list coverage in the MOF announcement's appendix, and whether post-cancellation exports are treated as "VAT-exempt (input credit reversed)" or "deemed domestic sales (taxable)" — net burden under the two mechanisms can differ by a factor of 2–3x. Referencing the April 2026 precedent (industry price increases of 5–13%, implying a pass-through rate range of 38%–100%), where price hikes occurred during a period of strong orders, the indicative power of a 60% neutral pass-through rate is limited. Sell-side consensus (2027E attributable profit of RMB 1.80–1.86 billion) differs from our estimate (RMB 1.35–1.65 billion) by about 20%; the two bases are not directly comparable, but if the pass-through rate falls short, downward-revision risk is real. A timing warning is also warranted: in 2026Q4–2027Q1 customers have an incentive to front-load orders ahead of the effective date (April precedent: Q1 concentrated procurement inflated figures, followed by a sharp drop after effectiveness) — apparent revenue beats at that point will not represent a genuine demand inflection.
Key evidence:
The balance sheet is the thickest part of this company: no bank borrowings, net cash at one-third of market cap, PB of 2.12x at roughly the 14th percentile of the past 10 years, and book value per share of approximately HKD 3.92 — more than half above the share price. But its "protective power" must be measured precisely: October buybacks totaled approximately 13.95 million shares, costing approximately HKD 120 million — only 0.2% of market cap — a signal of management attitude with no pricing support for the HKD 51.38 billion market cap; a payout of approximately 200% (2026 interim dividend of HKD 0.20 implies a payout of approximately 183% of H1 attributable profit) means net cash is flowing out at roughly RMB 2 billion per year, and "34% of market cap" is a static, monotonically declining reading; roughly 70% of revenue is USD-denominated, and 2026H1 saw net FX losses of RMB 164 million — RMB appreciation scenarios would accelerate the erosion. Earnings cash conversion is the main financial blemish: 2025 OCF/net profit was only 0.46 and FCF turned negative for the first time (revenue growth came at the cost of working-capital advances — receivables + inventories + other receivables rose RMB 1.34 billion combined, equal to 54% of the revenue increment); the recovery to 1.30 in 2026H1 is an improving signal, but it is only a half-year reading, and receivables and inventories will re-inflate in the Q4 shipment season.
Key evidence:
During the 2022 US disposables shock, a -11.7% revenue decline led to a -52.5% drop in attributable net profit (-48.0% adjusted) — not a hypothesis, but a transmission experiment that already happened. Under the current structure, this risk has two new amplifiers: receivables-side concentration (66%/84%) exceeds revenue-side concentration, so a single customer also constitutes credit exposure; and the HNB second curve remains concentrated within the same customer system. Offsetting factors: the direction of customer concentration is improving (the largest customer's share fell further from roughly 40.1% in 2024; for the accurate 2025 figure see the annual report excerpt quoted in this section), plus diversification via the second HNB customer, own brands (20.4% share), and medical businesses. Note also: the 2022 profit halving had multiple stacked causes (gross margin compression, own-brand contraction, disposables cannibalization), and the 4.5x leverage is an extrapolated upper bound on the attributable basis — mechanically applying it to 2026's structure would overstate marginal impact. On the equity side, the ≤3.5% reduction plan by the second-largest shareholder EVE Energy (holding approximately 30.25%) hangs overhead until July 2027 (historically executed in only 1 of 4 tranches, for 27.355 million shares), hedged against the company's buybacks.
Key evidence:
The valuation judgment must present three bases simultaneously: the company's self-reported adjusted net profit adds back share-based compensation in full (FY2025: RMB 468 million, 44% of attributable profit) and excludes medical-business losses — an aggressive basis. The 18.4x computed on it skews optimistic; 25–26x ex-SBC is closer to the true cost of shareholder returns. The low PB percentile has weak indicative power given three consecutive years of earnings decline and one-third of net assets being cash (low PB with low ROE is the classic shape of a value trap, not evidence of mispricing); probability-weighted fair value of HKD 7.85 is about 6% below the current price, while the base-case midpoint of HKD 8.55 is about 3% above — the current price sits at roughly the 63rd percentile of the bear–bull distribution, with symmetric, slightly negative odds. The conclusion is "a quality recovery story priced fairly": quality is not in doubt (net cash + technical moat + dual-inflection direction), but there is no meat in the price (the base-case recovery is already priced; the remaining expectation gap rests on two face-down cards — the rebate pass-through rate and China HNB). This explains why a neutral camp (Daiwa at 9.4) coexists with a buy camp (mean 12.18) — the disagreement is not about facts, but about the 2027 pass-through rate assumption.
| Metric (RMB 100 mn) | FY2023 | FY2024 | FY2025 | 2026H1 (latest period) |
|---|---|---|---|---|
| Revenue | 11,203.03 (restated) | 11,799.17 | 14,256 | 7,209 |
| Revenue YoY | -7.9% | +5.3% | +20.8% | +19.9% |
| Net profit attributable to shareholders | 1,645 | 1,303 | 1,064 | 572 |
| Net profit YoY | -34.5% | -20.8% | -18.4% | +16.2% |
| Adjusted net profit (company basis) | 1,942 | 1,509 | 1,530 | 757 |
| Adjusted profit YoY | — | -22.3% | +1.3% | +2.6% |
| Gross margin | 38.7% | 37.4% | 34.1% | 32.2% |
| Net margin | 14.7% | 11.0% | 7.5% | 7.9% |
| Operating cash flow | 3,193 | 1,753 | 487 | 743 |
| Free cash flow | 2,004 | 856 | -49 | +247 |
| Cash + cash-like assets | — | — | 15,782 | 15,502 (as of 2026-06-30) |
| Interest-bearing debt | — | — | 2,226 | 649 (as of 2026-06-30) |
| Debt-to-assets ratio | — | — | 23.3% | 18.3% |
Wait — I must not alter numbers. Correcting below.
| Metric (RMB 100 mn) | FY2023 | FY2024 | FY2025 | 2026H1 (latest period) |
|---|---|---|---|---|
| Revenue | 112.03 (restated) | 117.99 | 142.56 | 72.09 |
| Revenue YoY | -7.9% | +5.3% | +20.8% | +19.9% |
| Net profit attributable to shareholders | 16.45 | 13.03 | 10.64 | 5.72 |
| Net profit YoY | -34.5% | -20.8% | -18.4% | +16.2% |
| Adjusted net profit (company basis) | 19.42 | 15.09 | 15.30 | 7.57 |
| Adjusted profit YoY | — | -22.3% | +1.3% | +2.6% |
| Gross margin | 38.7% | 37.4% | 34.1% | 32.2% |
| Net margin | 14.7% | 11.0% | 7.5% | 7.9% |
| Operating cash flow | 31.93 | 17.53 | 4.87 | 7.43 |
| Free cash flow | 20.04 | 8.56 | -0.49 | +2.47 |
| Cash + cash-like assets | — | — | 157.82 | 155.02 (as of 2026-06-30) |
| Interest-bearing debt | — | — | 22.26 | 6.49 (as of 2026-06-30) |
| Debt-to-assets ratio | — | — | 23.3% | 18.3% |
Note: Adjusted net profit is the company's own basis (full add-back of share-based compensation, exclusion of atomized medical losses); the degree of aggressiveness is discussed in Section 8. FY2023 revenue is per the retrospective restatement in the 2025 annual report (originally disclosed as RMB 111.68 mn... corrected: RMB 11.168 bn). TTM (as of 2026-09-30) revenue approx. RMB 15.2 bn, net profit attributable to shareholders approx. RMB 1.19 bn, adjusted net profit approx. RMB 1.557 bn (YoY +1.8%).
Reasons for metric changes (YoY ≥ ±20% excerpted, all with management explanations):
Q3 single-quarter revenue was RMB 3.946 bn, YoY -6.0%, QoQ +17.7%; profit for the period RMB 365 mn, YoY +15.2%, QoQ +18.0%; adjusted profit RMB 452 mn, YoY +1.8%. For the first nine months, revenue was RMB 11.155 bn (+9.3%), profit RMB 937 mn (+15.8%), adjusted RMB 1.209 bn. Structurally, three up and one down: US — began delivering flavored e-vapor products to its core customer with launches proceeding as planned; e-vapor ODM revenue turned positive at YoY +1.8%; HNB — revenue of RMB 397 mn, QoQ +33.2% but YoY -47.8% (base inflated by large-scale shipments to a strategic customer in 2025Q3); established a comprehensive HNB partnership with a new tobacco customer during the period; Medical — revenue of RMB 96 mn, YoY +40.6%; CIRS Biotechnology continued to advance external equity fundraising; Hedge — the market's positive read on sequential improvement is mixed with stocking-up motivation ahead of the tax refund taking effect in April 2027; a single quarter's data cannot yet prove a true demand inflection (see C3). Overall, Q3 continues the pattern of "weak revenue growth, margin recovery, structural transition," consistent with the interim report.
Business model in brief: Asset-heavy ODM manufacturing as the core (roughly 80% of revenue from corporate customers; 97% of revenue recognized at a point in time — i.e., upon shipment, not recurring subscription). The in-house FEELM ceramic atomization coil creates "an ODM with pricing power": ODM-side gross margin of 32–37%, far above typical EMS providers (estimated 15–25%), and even above downstream brand RELX (26–35%). Own brand VAPORESSO (No.1 globally in open systems) plus LANZHI beauty contribute roughly 20% of revenue; atomized medical (CIRS Biotechnology; ANDA first-to-file + co-development with pharma) is the incubating third growth curve. Overall pricing power is absent: gross margin has declined for four consecutive years (38.7%→37.4%→34.1%→32.2%), attributed to a rising share of low-margin products (disposables, HNB ramp-up).
Cash-content test of earnings: OCF/net profit for 2023–2025 was 1.94→1.35→0.46, recovering to 1.30 in 2026H1; FCF/net profit 1.22→0.66→-0.05→+0.43 (2026H1). 2025 was a clear warning year: of the RMB 2.46 bn revenue increase, about 54% was absorbed by receivables and inventory advances; book profit did not convert to cash in tandem — 2026H1 recovered, but full-year validation is needed. Recurring earnings: the company's self-reported adjusted basis is aggressive (FY2025 fully adds back SBC of RMB 468 mn = 44% of net profit attributable, and additionally excludes medical losses). Recurring net profit attributable after removing one-off items (adding back litigation settlement of RMB 176 mn, excluding government grants of RMB 38 mn) is approx. RMB 1.20 bn, between the reported RMB 1.064 bn and the aggressive RMB 1.53 bn — this report's valuation uses the ex-SBC basis as a conservative anchor.
Return on capital: All-in ROIC approx. 4.4% (diluted by approx. RMB 15.8 bn of cash-like assets); operating ROIC ex-cash approx. 9.1% — above typical contract manufacturing but below the 15% true-moat threshold, within the reasonable range of a "technology-premium ODM," not a money printer.
Capex quality: Cash-basis CapEx/depreciation converged from 4.39 (2023 expansion peak) to 1.88 (2025); the company's self-reported 2025 figure was RMB 1.30 bn (including the headquarters building and capitalized R&D; cannot be split into maintenance vs. growth — no breakdown disclosed, maintenance spend cannot be determined). The capacity expansion peak has passed; 2026H1 capex was RMB 496 mn, YoY -37%.
Red flags: ① 2025 FCF turned negative, OCF/net profit 0.46 (see above); ② largest customer accounts for 66% of trade receivables, deteriorating from 57% the prior year; ③ aggressive adjusted basis; ④ payout of approx. 200% supported by existing cash; ⑤ R&D capitalization rate jumped from 7.6% to 16.8% (mainly from the medical pipeline). The first four are already priced into the thesis; the fifth is covered in Section 8.
Consistency of words and actions: pragmatic, no major misses observed. Verifiable promise-delivery record: ① 2024 annual report promised "2025 will be the key landing phase for HNB" → achieved scale shipments in 2025H2, full-year HNB revenue of RMB 1.287 bn — delivered; ② 2025 annual report promised "milestones to be met on schedule in 2026" → 9M26 revenue +9.3%, US flavored products delivered as planned, one new tobacco HNB customer added, coverage of 9 markets — preliminarily delivered; ③ atomized medical "establish partnerships with international pharma companies" → three ANDAs accepted by the FDA and confirmed as first-to-file, the Florida plant passed cGMP inspection, milestone payments received from partners — milestones delivered, but "external fundraising to ease the burden" has not yet materialized (9M26 medical segment still lost RMB 175 mn). Management's communication style centers on milestones with little quantitative revenue guidance — honest, but leaves room for interpretation.
Shareholder friendliness: generally friendly, but the incentive basis keeps expanding. Dividends: 10→10→40 HK cents (2023–2025), plus an interim 20 HK cents in 2026; dividend yield approx. 4.8% (at 40 HK cents / HK$8.31). Buybacks: RMB 665 mn in 2024, RMB 200 mn in 2025 (for share awards) + intensive buybacks from October 2026 (approx. HK$120 mn as of 10-30; the Board explicitly stated "the share price does not reflect intrinsic value"); no record of new share issuance or placements. Hedge: in 2025, 67.675 mn share options were granted (including 61.0 mn to the Chairman, with vesting conditions tied to market cap of HK$300 bn/400 bn/500 bn — 6–10x the current market cap, an extremely high bar, effectively a long-term option); total options granted but unexercised approx. 239 mn shares (approx. 3.9% of share capital); SBC rose from RMB 270 mn to 468 mn, with expense recognition slower than grants.
Risk signals: ① the Chairman and CEO roles are both held by Chen Zhiping (the company itself acknowledges deviation from the Corporate Governance Code C.2.1); ② related-party procurement: the second-largest shareholder EVE Energy is also a battery supplier — 2025 related-party purchases of RMB 388 mn, 2026 cap of RMB 900 mn (pricing comparison mechanism and annual caps in place, but amounts expanding rapidly); ③ EVE Energy's reduction plan renewed for a fifth consecutive year (≤3.5%); ④ zero provision for the California antitrust MDL litigation (see Section 8). Overall profile: management is pragmatic and credible, but governance carries a combination discount of "concentrated control + related-party transactions + overhang from share reductions."
| Segment | 2025 revenue share | YoY | Gross margin | Business logic in one sentence |
|---|---|---|---|---|
| ToB e-vapor & special-use (incl. technical services) | 70.5% | +10.5% (estimated) | Not separately disclosed (incumbent mainstay) | ODM for global tobacco giants/brands; compliance certifications form an order barrier; US 28.6%, Europe 40.5% |
| ToB heated-not-burn (HNB) | 9.0% | +475.4% | Below incumbent business (a main driver of gross margin decline) | Second growth curve; shipments to a single strategic customer in 9 markets + a second customer added in Q3 |
| Own brands (VAPORESSO + LANZHI beauty) | 20.4% | +17.6% | Not separately disclosed | Global No.1 in open systems; Europe +15.7%/US +23.8%/beauty +65.8%; slowed to +1.9% in 2026H1 |
| Atomized medical (CIRS Biotechnology) | 2.0% (2026H1 standalone basis) | +24.8% (2026H1) | Segment loss (loss of RMB 132 mn in 2026H1) | Inhaled-delivery ANDA first-to-file + co-development with pharma; 2026H1 revenue RMB 147 mn |
| Atomized beauty | 0.3% | +65.8% (2025)/-26.2% (2026H1) | Investment phase | LANZHI home + professional beauty devices; still small in scale |
The company does not disclose gross margin by segment — a disclosure-quality gap. Profit drivers: inferred by "revenue share × margin structure," the ToB e-vapor incumbent business still contributes the bulk of gross profit (70.5% of revenue × relatively higher margin); HNB is the revenue growth engine but dilutes overall gross margin (one of the main drivers of the 34.1%→32.2% decline); medical is a cost sink. The generational shift in growth sources is clear: 2025 increments = HNB (+RMB 1.05 bn) + Europe compliance repatriation; 2026 increments = HNB sequential recovery + US flavored products ramping from Q4. Single-business concentration risk does not apply (multi-segment), but the combination of "profit driver (incumbent e-vapor) growing slowly, growth engine (HNB) carrying lower margins" means the gross margin center is unlikely to rebound in the near term.
Accounting red flags:
Cross-period consistency:
Conclusion: No fraud-level signals, but the combination of "aggressive adjusted basis + jump in capitalization rate + zero litigation provision + inconsistency between cash flow and MD&A statements" suggests investors should anchor valuation on the reported net profit attributable and the ex-SBC recurring basis (approx. RMB 1.2 bn), not the company's adjusted basis (RMB 1.53 bn).
Current Market Data and Percentiles: Share price HKD 8.31 (close on 2026-10-30), total shares 6.183 billion, market cap HKD 51.38 billion; net cash approximately RMB 14.85 billion (roughly HKD 17.5 billion, about HKD 2.83 per share). PE(TTM reported) 36.3x — 4% percentile over the past 1 year / 31% over 3 years / 54% over 5 years; PE(TTM adjusted) 28.0x; approximately 25–26x excluding SBC; PB 2.12x (18% percentile over 5 years / 14% over 10 years); PS(TTM) 2.87x. Earnings are at a trough (continuously declining gross margin + SBC peak + rising tax rate), so PE percentiles are mechanically distorted and for reference only; the low PB percentile is likewise of limited indicative value given low ROE (roughly one-third of net assets is cash). This report anchors primarily on absolute valuation and scenario distributions.
Peer Benchmarking (PE based on TTM):
| Company | PE(TTM) | Growth | Gross Margin | Core Difference vs. SMOORE |
|---|---|---|---|---|
| SMOORE International | 36.3 (reported) / 28.0 (adjusted) / approx. 25–26 (ex-SBC) | TTM adjusted +1.8%; 9M26 revenue +9.3% | 32.2% (2026H1) | Midstream ODM leader, technology premium |
| Philip Morris International PMI | approx. 31 | FY2025 revenue +7.3%, smoke-free volumes +12.8% | 68.7% (brand side) | Downstream brand giant, IQOS holds ~76% of global HNB — valuation ceiling reference |
| Japan Tobacco JT | approx. 33 | FY2025 revenue +13.4%, HTS volumes +38.6% | Not available | Ploom brand owner, market rumors of HNB cooperation with SMOORE (unconfirmed) |
| RLX Technology | approx. 2.8 | 2026Q2 revenue +14.8% | 35.4% | Market cap ≈ net cash, extreme policy/governance discount on China-exposed vaping assets — discount floor reference |
Market-Implied Expectations: Market cap HKD 51.38 billion − net cash HKD 17.5 billion = operating EV of approximately RMB 28.7 billion, which against TTM adjusted net profit of RMB 1.557 billion implies 18.4x (approximately 25–26x ex-SBC). Back-solving: priced at 12x FCFE for a mature ODM, the current price implies sustainable FCFE of approximately RMB 2.39 billion — about 3x the current reality (approximately RMB 0.8 billion); at 15x, implied adjusted net profit would need to rise from RMB 1.56 billion to approximately RMB 1.91 billion (+23%) and hold. In plain terms: the current price requires the company to grow adjusted earnings 25–50% within two years with gross margin stabilizing, whereas reality is TTM adjusted +1.8% with gross margin still declining. This expectation is not pure narrative — HNB dual clients and U.S. compliance are supported by industry-chain data (JT HTS +38.6%, PMI smoke-free +12.8%, ~70% of the U.S. illicit market awaiting clearance) — but the transmission links to SMOORE's orders (glo Hilo sell-through, second client ramp, flavored product ramp) remain unverified, and industry research (2026-09) shows that the bulk of 2025 global HNB volume growth went to PMI (71.5% share), while the BAT system SMOORE is effectively tied to holds only ~11%; the discount from industry β to company α must be accounted for.
Three-Layer Value (EPV): Asset value (floor) approximately HKD 3.92 per share (book value per share, back-solved from PB 2.12; of which net cash HKD 2.83); EPV with zero growth approximately HKD 1.45/share (sustainable FCFE of approximately RMB 0.8 billion ÷ cost of equity 10.5%, equity basis; range 1.13–1.91); growth options account for approximately 82.5% of the current price (calculated in this report) — i.e., the vast majority of the current price is not paying for the existing business, but for the realization of the HNB / U.S. compliance / China HNB options. This case hits a structural demand inflection (regulation-driven category switch), so EPV is only the floor, not the final verdict: whether growth deserves to be paid for is answered by the ramp scenarios and implied-expectation math below; the growth-quality gate (FEELM moat + dual-giant binding + net cash supporting reinvestment) preliminarily passes, but an option share of 82.5% means any card flipping wrong would also imply a sizable downside revision.
Three Scenarios and Odds (fair value range per share, HKD; probabilities adjudicated by this report):
| Scenario | Probability | Fair Range | Core Assumptions |
|---|---|---|---|
| Bear | 30% | 4.9–5.3 (midpoint 5.07) | Tax rebate pass-through of only 30–35% (2027 net profit impact approx. -RMB 0.67 billion) + HNB single-client slowdown/cut orders + U.S. enforcement reversal; 2027E adjusted approx. RMB 1.4 billion × EV/adjusted 10x (anchor: ODM comparable troughs at 10–12x and the company's own 2023–24 trough, not self-anchored to current price) + retained net cash approx. RMB 12.6 billion |
| Base | 50% | 8.2–8.9 (midpoint 8.55) | Tax rebate pass-through 60% (impact -RMB 0.41 billion) + HNB dual-client ramp (2027 HNB revenue RMB 3 billion+) + U.S. flavored products ramp + gross margin stabilizing at 32–33%; 2027E adjusted RMB 1.9–2.0 billion × EV/adjusted 14–16x (anchor: ODM comparables 12–18x midpoint + own trough range; PMI at 31x serves as brand-side ceiling reference) + net cash RMB 14.85 billion |
| Bull | 20% | 9.7–10.7 (midpoint 10.19) | China HNB national standard lands and SMOORE enters China Tobacco supply chain + U.S. enforcement clearance materializes + healthcare divestiture re-rating; ramp estimate: revenue 2026E RMB 15.2 billion → 2030E approx. RMB 27.5 billion (CAGR ~16%, driven by JT/PMI HNB demand × SMOORE share + U.S. compliance reflow + China increment) → exit-year net profit approx. RMB 3.7 billion (net margin 13.5%) × exit EV/adjusted 16–18x (anchor: growth premium tier between brand-side JT 33x / ODM steady-state 12–15x) @11% discount over 4 years + retained net cash RMB 18 billion → HKD 9.7–10.7, consistent with the range |
Odds annotation (vs. current price 8.31): bear-case midpoint -39.0%, base-case midpoint +2.9%, bull-case midpoint +22.6%; probability-weighted fair value approximately HKD 7.85, current price about 5.9% above it, sitting at roughly the 63rd percentile of the bear-bull distribution — odds symmetric but slightly negative, with no substantive margin of safety (base-case fair value lower bound of HKD 8.2 is below the current price, margin of safety approx. -1.3%). External anchor comparison: the buy-side sell-rating camp's mean of HKD 12.18 (+47% vs. current price) insufficiently accounts for the tax rebate impact and is not adopted as the base; Daiwa's "Hold" at HKD 9.4 (+13%) serves as a neutral reference; this report's bear case of 4.9–5.3 is significantly below both, because it independently constructed stress assumptions of failed pass-through + single-client slowdown; the framework (EV/adjusted 10x + retained cash) is not directly comparable with sell-side PE frameworks.
This Report's Earnings Forecast vs. Management Guidance vs. Sell-Side Consensus:
| Framework | FY2026E Revenue | FY2026E Net Profit | FY2027E Revenue | FY2027E Net Profit |
|---|---|---|---|---|
| This report | RMB 15.0–15.3 billion | RMB 1.20–1.28 billion (adjusted 1.61–1.72) | RMB 16.5–17.8 billion | RMB 1.35–1.65 billion (adjusted 1.75–2.1, incl. tax-rebate-neutral impact of -RMB 0.41 billion) |
| Management guidance | No quantitative guidance (qualitative: HNB milestones on schedule, U.S. compliant product delivery) | |||
| Sell-side consensus (Guosen / Huachuang) | — | RMB 1.24 / 1.14 billion | — | RMB 1.80 / 1.86 billion |
This report's 2027E is approximately 12–27% below sell-side: the divergence lies in the tax rebate pass-through rate (our 60%, street possibly full/high pass-through) and the HNB slope. This is the anchor for reconciliation at the next annual report.
Conclusion: Fairly priced (fair). Evaluate quality (net cash + technology moat + dual inflection direction) separately from price (base-case recovery already priced in; remaining expectation gap bets on unverified variables) — quality is good, price is neutral. Basis for the base-case exit multiple: EV/adjusted 14–16x, at the upper-middle of ODM comparables (historical 12–18x midpoint for companies such as Yingqu) and the company's own trough range (12–16x), justified by structural upgrade from rising HNB revenue share; the company's current trading multiple was not used for self-anchoring. Liquidity note: average daily turnover approximately HKD 70 million (~0.14% of market cap), intraday drop of as much as -15% on the 10-13 policy shock day; large allocations should be staged.
Global e-vapor (e-cigarette) retail size in 2025 was approximately USD 40–46 billion (Frost & Sullivan's ~USD 39.9 billion as the headline figure; aggregator Grand View's USD 45.7 billion only as cross-reference); HNB (heat-not-burn) approximately USD 28.8 billion in 2021 with higher growth (F&S 2020–25E CAGR 21.6%). Their combined penetration of the global nicotine market remains only in single digits (2.9%/3.7% in 2021) — large long-term room, but growth has clearly slowed recently: per Euromonitor, global legal vapor product volume grew only +7% in 2024, slower than nicotine pouches and HNB — the vaping industry has moved from a penetration-driven broad rally into a "regulation-driven structural switch phase." Compliant-basis CAGR over the next 3–5 years is approximately 8–15%, with HNB faster than vaping.
The structural demand-inflection chain (currently the industry's most important variable) can be quantified in three links: ① The U.S. "illicit → compliant" switch: illicit disposables account for roughly 70% of the U.S. vaping market (per BAT's 2024 annual report, ~USD 9.4 billion); FDA federal enforcement + state registry laws (3 states already effective, expanding to ~14 states by end-2025) continue to clear them out; post-enforcement in Louisiana, the legal market +28% and illicit channels -91% is a validated precedent; FDA successively approved NJOY menthol in 2024-06 and the first fruit flavors in 2026-05, with legal closed-pod supply returning — SMOORE's core client Vuse holds a 50.2% value share of U.S. closed-system consumables and is one of the largest beneficiaries of the reflow. ② The second global wave of HNB volume: JT FY2025 HTS shipments of 11.3 billion sticks (+38.6%), Ploom's Japan share 12.6% → 14.4%, additional investment of approximately JPY 800 billion over 2026–28; PMI HTU shipments +11%, IQOS holds ~76% of global HNB; HNB already accounts for ~46% of Japan's tobacco industry (deepest globally), with double-digit growth in Europe. ③ The China HNB zero-to-one option: the mandatory national standard for heated tobacco went out for public comment on 2026-07-28 and completed WTO/TBT notification on 08-19 (international comment deadline 10-18); per "implementation 6 months after publication," earliest landing mid-2027; sell-side estimates an initial pilot of "6+1 provinces," first-year quota of 600,000 cases (~30 billion sticks), and 10% penetration by 2030. Key discount item: the benefits of this three-link chain do not accrue equally to SMOORE — the U.S. link transmits directly through Vuse (highest certainty); the incremental HNB volume flows mainly to PMI (71.5% of global HNB volumes, supply chain at companies like Yingqu Technology) and JT, while SMOORE's publicly disclosed binding is the BAT glo Hilo system with ~10.7% share + one unnamed new client; for the China link, there is no announcement evidence that SMOORE can enter the China Tobacco supply chain. Industry β is real; company α must be verified link by link.
Upstream: batteries (EVE Energy lineage — both SMOORE's second-largest shareholder and a supplier), chips/main controllers, ceramic heating elements, structural parts — standard electronic components are highly competitive with weak bargaining power; the core barrier component, the ceramic atomizing coil, is developed in-house in a closed loop by SMOORE (FEELM), where profit is retained. Midstream: ODM/OEM manufacturing, with Shenzhen hosting ~1,200 equipment manufacturers and ~600 enterprises; severe mid/low-end overcapacity and brutal disposable price wars (unit prices driven down to USD 1–2); but compliant high-end capacity is scarce — PMTA/TPD/China monopoly licensing requirements on manufacturing consistency and GMP effectively lock in the list of compliant suppliers. Downstream: brand owners (BAT Vuse with 40.3% global vaping share, Altria/NJOY, JTI Ploom, JUUL, ELFBAR, RLX) and channels (mainly U.S. convenience stores + gas stations) — retail has the thickest gross margins but the heaviest expenses; brand owners' net margins run 10–20%. SMOORE sits midstream yet captures profits beyond its position in the chain: it maintains strong bargaining power with BAT/RLX et al. via patents and yield (manufacturing gross margin 32–37% vs. ordinary EMS 15–25%, even above brand-side RLX's 26–35%), at the cost of high single-client dependence (~80% of revenue from enterprise clients). Gross profit mainly stays at the link that "controls atomizing coil technology + compliance certification" — precisely SMOORE's position.
Demand drivers: harm-reduction conversion of ~1.1 billion smokers globally (combined vaping + HNB penetration in single digits) + compliant demand reflow from regulatory enforcement (U.S./UK) + product-form upgrades (large capacity, reusable). Supply structure: China accounts for ~90–95% of global production; on the equipment manufacturing side, F&S (2019) CR5 is only 30.5% — SMOORE ranks first at 16.5%, second at 6.5%, with 3rd–5th each <3%; per company disclosures, its share rose to 22.8% in 2022, exceeding the combined total of the 2nd–5th players (company self-reported, not independently verified); Sullivan-basis 2024 share approximately 13.1% (both figures presented side by side: the difference lies in statistical scope and timing; trend consistently upward). Entry barriers: ① patents (SMOORE has filed 3,408 cumulatively, 46.1% invention patents); ② compliance certification (PMTA takes years and huge costs per product; China tobacco monopoly production licenses + quota management); ③ automation scale (UPH 7,200 units/hour); ④ switching costs of major-client qualification. Substitution threats: diversion to nicotine pouches (ZYN shipped 794 million cans in 2025) and HNB — for SMOORE this is "heads one wins, tails you win too" (positioned in both vaping and HNB). Competitive intensity is polarized: a red ocean in low-end disposables, an orderly and high-quality-profit compliant pod/HNB segment — SMOORE's strategy is precisely to avoid the red ocean and entrench at the high end.
The industry is mid-stage in its growth life cycle; after the 2022–2024 downturn from "U.S. illicit disposables shock + China domestic-market national standard contraction," 2025–2026 is at an "upward inflection driven by compliance restructuring" (corroborated by SMOORE FY2025 revenue +20.8%, a record high, and 2026H1 +19.9%). Leading indicators: FDA warning letters/seizure volumes and the pace of state registry law expansion, PMTA approval cadence, brand-owner guidance (BAT's double-digit growth guidance for new categories in 2026, JT/PMI investments), and SMOORE's quarterly revenue growth. Regulatory map: U.S. — PMTA licensing + enforcement discretion (only dozens of products authorized, all pod-based); the 2026-05 fruit-flavor clearance + updated enforcement guidance marks a major pivot, but it is discretionary rather than statutory and reversible. EU/UK — UK banned disposables effective 2025-06-01 (within 3 months, 85% of disposable users switched to refillables, but first-month gray "pseudo-pod" sales of 5.3 million units vs. 1.4 million legitimate pods — conversion is real but diluted by gray products); Belgium and France followed with bans; EU TPD revision in progress. China — the E-Cigarette Management Measures impose full-chain monopoly licensing + quota management + flavored-product ban domestically (SMOORE's domestic share already down to only ~2%); exports require licensed filing; the 2026-04 and 2026-10 rounds of export tax rebate cancellations represent a supply-side cost repricing; the HNB national standard is advancing. Japan — nicotine e-liquids banned, HNB encouraged. Overall direction: the global regulatory mainline of "clearing illicit players and raising barriers" is neutral-to-positive for compliant leaders; risks lie in enforcement falling short (US/UK) and policy reversals.
See the valuation benchmarking table in Chapter IX (PMI/JT/RLX juxtaposed with SMOORE on a like-for-like basis). Additional positioning: PMI/JT are brand owners (downstream); RLX is brand + partial in-house production; ELFBAR/iMiracle (approx. 22% share of Western European disposables) and JUUL (FDA authorization to return as of 2025-07) are two other variables in U.S. compliance; SMOORE is the world's only midstream leader combining "No.1 manufacturing share + in-house technology + brand diversification." Joyetech represents the path without core technology premium that SMOORE surpassed, highlighting the relative advantage of the FEELM model.
Niche leader with rising share: No.1 globally in vaping device manufacturing (16.5% → 22.8%, company basis), with an upward share trend; moat = FEELM ceramic coil technology closed loop + automation + major-client qualification barriers. Three soft spots in this positioning: client concentration (largest client nearly 40%), the limits of ODM bargaining power (price concessions to major clients in 2022, gross margin -10.3pct), and its binding partner's share disadvantage in the HNB era (BAT system holds only ~10.7% of global HNB vs. PMI's 71.5%). Note on market position figures: SMOORE's "global No.1" share data mainly come from F&S (as relayed in the prospectus) and company self-disclosure, with both figures coexisting at different points in time and no independent third-party verification — a rough cross-check of "share × market size ≈ revenue" (22.8% × ~USD 40 billion retail ≠ SMOORE's USD 2 billion factory-gate revenue, due to retail/factory-gate and statistical-scope differences) is internally consistent but of limited precision.
A generic financial framework for the e-cigarette manufacturing industry would miss two defining variables: regulation is the switch of demand, and product generations are the migration path of orders. Every generational switch in history has rewritten manufacturers' order maps: 2018–2020 pod systems (rise of Juul/Vuse, SMOORE's first volume wave) → 2021–2023 disposables (explosion of gray brands like ELFBAR; SMOORE, insisting on compliant pods, saw revenue -11.7% and profits halved) → 2024–2026 compliant pod return + HNB rise (European disposable bans + U.S. enforcement + HNB domestic production expectations). SMOORE's stock price history is a history of generational switching: the five-year -77% decline corresponds to the gap window of "the previous generation's dividend exhausted, the new generation not yet delivered." The current switching window has three parallel tracks: the U.S. (enforcement clearing the 70% illicit market; the legal basis is enforcement discretion rather than authorization — reversibility is why this report lowered C2 confidence); Europe (disposable bans in effect; gray "pseudo-pods" are a disturbance factor in conversion quality); China (if the HNB national standard lands in 2027, whether the China Tobacco system procures equipment via tendering or designated manufacturing will determine whether SMOORE can share in it; currently no announcement evidence). Implications for investors: this industry's orders are not a continuous curve but a step function; the key tracking points are regulation effective dates and clients' new-product launch dates (the tracking checklist in Chapter XII of this report is designed accordingly), and monthly China e-cigarette export values are the most timely leading indicator (the -20.9% single-month drop in exports after the first tax rebate adjustment in 2026-04 is precedent).
Overall rating: Neutral (confidence 0.55, 12 months). SMOORE is a composite hand of "quality assets + already-priced inflection point + unverified variables": net cash of RMB 14.85 billion (34% of market cap) and its leading ODM position form the quality floor; there is industry-chain evidence supporting the HNB and US compliance directions, but the current price of HKD 8.31 represents only a 2.8% discount to the baseline fair-value center and roughly a 6% premium to the probability-weighted fair value—the odds are symmetric and slightly negative. This is neither an oversold opportunity nor does it exhibit short-selling characteristics (quality and cash provide downside support); it is a case of waiting for verification rather than rushing to take a stance. Strategically: only below HKD 8.2 (entering the lower bound of our own fair-value range) with fundamentals intact does an entry point with attractive odds emerge; above HKD 8.9 would mean the baseline recovery has materialized, requiring a reassessment of upside; below HKD 6.5 enters bear-case pricing territory, requiring verification of whether it is driven by failed pass-through of the tax rebate cut or customer order cancellations.
Risk and catalyst alerts (presented in writing for tracking): Key milestones over the next 6–12 months are, in sequence—Q4/full-year financial update (if the quarterly disclosure practice continues, January–February 2027: to verify the slope of US flavored products and HNB sequential trends), FY2026 annual report (mid-March 2027: whether adjusted net profit falls within the RMB 1.61–1.72 billion range and the final dividend level), export tax rebate elimination taking effect (2027-04-01: whether export volumes are abnormally front-loaded before the effective date and the slope of the decline afterward), the release window for China's HNB national standard (2026Q4–2027H1), the identity and order size of the second HNB customer, Chuan Si Bio's external financing/ANDA approvals, and the expiry of EVE Energy's stake-reduction plan (2027-07-03). Downside triggers: gross margin falling below 30% in 2027 (a signal that pass-through is under 40%), HNB revenue turning negative year-over-year in 2027, the largest customer cutting/moving orders or introducing a second supplier, or FY2026 adjusted net profit below RMB 1.5 billion. Liquidity note: average daily turnover is about HKD 70 million; volatility amplifies on policy shock days, so position building should be done in tranches.
This report is based on public information as of 2026-11-01. The price anchor is the HKEX closing price of HKD 8.31 on 2026-10-30 (close already completed); currency conversion uses RMB 1 ≈ HKD 1.179, with conversion timing noted in the text. Adjusted net profit follows the company's self-reported basis; this report also provides an SBC-excluded basis as a conservative anchor.